Results 61 to 70 of about 1,428 (167)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Abstract 2235: Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on liver tumorigenesis in obese and diabetic mice

, 2017
Obesity, diabetes mellitus, and their related metabolic abnormalities are associated with increased risk of hepatocellular carcinoma (HCC). Sodium glucose cotransporter (SGLT)-2 inhibitors, recently approved anti-diabetic agents, are expected to ...
Koki Obara, Yohei Shirakami, Takayasu Ideta, Masaya Ohnishi, Masahito Shimizu, Mitsuru Seishima, Hiroyasu Sakai, Takuji Tanaka   +7 more
core   +1 more source

Changes in the eGFR in the groups according to the eGFR at baseline (0 months) before and after the initiation of tofogliflozin (n = 102).

, 2023
(A) The closed (black) circles and open (white) squares indicate subjects in the normal- (≥60 mL/min/1.73 m2, n = 68) and low- (2, n = 34) eGFR groups, respectively. *P
Takuma Izutsu (10305465), Hideyuki Inoue (156340), Tomoko Yamasaki (1898185), Hiroyuki Ito (339050), Toshiko Mori (10305468), Suzuko Matsumoto (10305462), Michiko Togane (339061), Shinichi Antoku (339057)   +7 more
core   +1 more source

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

Clinical Pharmacology: Advances and Applications, 2023
Shosaku Nomura,1 Akira Shouzu,2 Takehito Taniura,3 Yoshinori Okuda,4 Seitaro Omoto,5 Masahiko Suzuki,6 Tomoki Ito,7 Nagaoki Toyoda8 1Center of Thrombosis and Hemostasis, Kansai Medical University Medical Center, Moriguchi, Japan; 2Division of Diabetes ...
Nomura S, Shouzu A, Taniura T, Okuda Y, Omoto S, Suzuki M, Ito T, Toyoda N   +7 more
doaj  

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Fig 3 -

, 2023
Relationships between the change in the eGFR after the initiation of tofogliflozin and (A) HbA1c at the baseline, (B) eGFR at the baseline, (C) change in HbA1c after the initiation of tofogliflozin and (D) change in serum uric acid concentration after ...
Takuma Izutsu (10305465), Hideyuki Inoue (156340), Tomoko Yamasaki (1898185), Hiroyuki Ito (339050), Toshiko Mori (10305468), Suzuko Matsumoto (10305462), Michiko Togane (339061), Shinichi Antoku (339057)   +7 more
core   +1 more source

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

Effect of tofogliflozin on visceral fat inflammation of obese mice.

, 2019
Mice were fed either HFD or NC with/without tofogliflozin. (A) the gene expression of Spp1 and Tnfa in VAT. (B) Serum osteopontin concentration of the indicated mice was assessed by ELISA (n = 7–10) **P < 0.01; NS: not significant by the non-parametric ...
Kohsuke Shirakawa (4233655), Keisuke Inoue (764054), Jin Endo (4233664), Wataru Yano (764051), Yoshinori Katsumata (630787), Motoaki Sano (276939)   +5 more
core   +1 more source

Ketoacidosis without significantly hyperglycaemia - is it possible?

Journal of Education, Health and Sport, 2017
Introduction and aim of the study. Currently only minimal information is available regarding ketoacidosis without significant hyperglycemia. Some study describe that the sodium –glucose cotransporters (SGLT) may alter the normal balance between ...
Michał Budzyński, Joanna Pekar, Justyna Magdalena Skolarczyk, Monika Tadla, Katarzyna Skórzyńska-Dziduszko   +4 more
doaj   +3 more sources